A Phase 2a Multi-Center Study of 18F-FDG PET, Safety, and Tolerablity of AZD0530 in Mild Alzheimer's Disease

Project: Research project

Project Details


AZD0530 is an inhibitor of Src and Abl family kinases. It has been developed as treatment for malignancies because these kinases play a role in tumor invastion and prolifertion. However, the Src family kinases (SFKs) are highly expressed in the brain and have major effects on synaptic plastcity. Moreover, recent studies have shown that FYN is aberrantly activated by specific conformations fo the Amyloid Beta (AB) peptide from Alzheimer's Diesease (AD). Genetic deletion of FYN rescues AD deficits in preclinical models. This project will test the potential benefit of AZD0530 for Alzheimer's Disease modifctaion.
Effective start/end date7/1/155/31/18


  • University of Southern California (CTAFYN067//4UH3TR000967-02)
  • National Center for Advancing Translational Sciences (CTAFYN067//4UH3TR000967-02)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.